Previous 10 | Next 10 |
2023-08-02 08:23:00 ET Summary We’ve seen a shift in analyst sentiment over the last two weeks when looking at data in This Week in Earnings and STOXX 600 Earnings Outlook report. For the S&P 500, the week ending July 28th saw a total of 2,444 FY1 EPS revisions over a 7...
2023-08-02 06:02:15 ET Summary Clearance given by FDA to initiate higher 50 mg dosing of CTI-1601 for patients with Friedreich's Ataxia for phase 2 study; results from this cohort expected 1st half of 2024. Clearance given to initiate open-label extension study of CTI-1601 for Fri...
2023-08-01 05:45:00 ET Biogen 's (NASDAQ: BIIB) biggest problem in recent times has been growth. The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in declining sales. All this has weighed on share performance too, ...
2023-07-31 07:45:00 ET Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) will soon likely be going head to head in the market for therapies that treat Alzheimer's disease. Both drug developers see the market for such medicines as being a major one in the coming years, and thei...
2023-07-31 06:13:00 ET Shares of Reata Pharmaceuticals (NASDAQ: RETA) recently jumped about 54% higher in a single trading session. This biotech stock was already way up this year thanks to the recent approval of its first drug, Skyclaris, in February. A juicy buyout offer with ...
2023-07-29 20:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-07-28 17:20:10 ET Summary Biogen Inc. has announced plans to acquire Reata Pharmaceuticals, Inc. for $7.3 billion, validating the potential of Skyclarys. Skyclarys, the sole FDA-approved treatment for Friedreich's ataxia, has considerable market potential, justifying the acqu...
2023-07-28 16:00:00 ET Summary Mounjaro may rake in $25B of annualized sales by 2026, exceeding ABBV's Humira. This naturally explains Mr. Market's optimism surrounding the LLY's stock thus far. The same has been witnessed with NVO, with accelerating annualized obesity related rev...
2023-07-28 13:22:08 ET Larimar Therapeutics ( NASDAQ: LRMR ), which has a candidate in phase 2 for Friedreich's Ataxia ("FA"), is up 22% in Friday afternoon trading, a beneficiary of Biogen's ( BIIB ) announcement to acquire Reata Pharmaceuticals ( RETA ) for more th...
2023-07-28 12:49:08 ET Shares of Reata Pharmaceuticals Inc ( NASDAQ: RETA ) opened more than 50% up this morning after Biogen Inc ( NASDAQ: BIIB ) said it will buy the pharma company for $7.3 billion. Why is Biogen making this acquisition? The all-cash agreement values e...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...